USANA Health Sciences Inc. - 10-Q Summary
Business Context and Reporting Period
This is a Quarterly Report (Form 10-Q) for USANA Health Sciences Inc. for the period ended September 27, 1997. The company operates in the nutritional industry, selling products through a network of independent distributors. As of October 28, 1997, there were 6,384,619 shares of common stock outstanding.
Key Financial Metrics
| Metric | Quarter Ended Sep 27, 1997 | Nine Months Ended Sep 27, 1997 |
|---|---|---|
| Net Sales | $22,872,592 | $61,572,891 |
| Gross Profit | $18,063,689 | $48,610,502 |
| Gross Margin | 79.0% | 78.9% |
| Net Earnings | $1,855,826 | $4,640,801 |
| Earnings Per Share (Basic) | $0.29 | $0.73 |
| Operating Cash Flow (9mo) | $5,533,635 | |
| Cash and Equivalents | $2,809,793 (as of Sep 27, 1997) | |
| Working Capital | $3,984,649 | |
| Debt (Line of Credit) | $0 (Paid off during period) |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 42.2% for the quarter and 50.6% for the nine-month period compared to 1996. Growth was driven by new product introductions, a growing distributor base (approx. 82,000 current distributors vs. 52,000 in 1996), and a price increase phased in during Q3.
- Profitability: Net earnings reached record highs, increasing 27.3% for the quarter and 14.7% for the nine-month period. Earnings growth outpaced sales growth due to better management of distributor incentives and SG&A expenses as a percentage of sales.
- Cost Structure: Cost of sales remained stable at 21.0% of net sales for the quarter. Distributor incentives decreased to 45.6% of sales for the quarter (down from 45.9% in 1996) due to a new pricing structure and Leadership Bonus Program changes.
- Liquidity: The company paid off its $1.5 million line of credit balance. Cash and cash equivalents increased by $1.7 million to $2.8 million. The current ratio improved from 1.05 to 1.58.
Outlook, Risks, and Management Commentary
- Expansion Plans: USANA announced plans to expand into Australia, New Zealand, and the Caribbean in fiscal 1998. Initial sales in Australia/New Zealand are expected in Q1 1998. The company expects to spend an additional $3.0 million on inventory, capital expenditures, and operating costs for this expansion.
- Product Strategy: New products were introduced at the July 1997 Annual International Convention. A new pricing structure and distributor retention programs (including a co-branded credit card) were implemented to improve margins and distributor loyalty.
- Legal Proceedings: International Nutrition Company (INC) has sued USANA for patent infringement regarding the Proflavanol product. A French court recently ruled that INC does not own the patent in question; this decision is on appeal. If upheld, INC may be barred from proceeding. USANA intends to vigorously defend the action.
- Forward-Looking Statements: Management cautions that actual results may differ due to risks including the outcome of legal proceedings, the success of international expansion, and general market conditions.
Investor Verification Checklist
- Verify the status of the patent infringement lawsuit with International Nutrition Company and the outcome of the French appeal.
- Monitor the execution of the international expansion into Australia and New Zealand, specifically the $3.0 million capital requirement and Q1 1998 sales timeline.
- Confirm the sustainability of the 45.6% distributor incentive ratio following the recent pricing and bonus program changes.
- Review the impact of the new product introductions on inventory levels and potential obsolescence provisions.
- Assess the company's ability to maintain the 79% gross margin as raw material and labor costs fluctuate.